News

Alembic Pharmaceuticals completes USFDA RRA for its bioequivalence facility

The RRA was conducted from 22nd August, 2022 to 26th August, 2022.

  • By IPP Bureau | August 29, 2022

Alembic Pharmaceuticals Limited has successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Bioequivalence Facility, Bio-analytical division, located at Vadodara, without any observations.

The RRA was conducted from 22nd August, 2022 to 26th August, 2022.

Other Related stories

Startup

Digitization